Assetmark Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Assetmark Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 83.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 20,819 shares of the biopharmaceutical company’s stock after selling 106,802 shares during the quarter. Assetmark Inc.’s holdings in Regeneron Pharmaceuticals were worth $11,706,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Salomon & Ludwin LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $31,000. Traub Capital Management LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $38,000. Berbice Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 60 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 35 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 2.5%

Shares of Regeneron Pharmaceuticals stock opened at $803.17 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The firm has a market cap of $84.91 billion, a PE ratio of 19.33, a PEG ratio of 2.16 and a beta of 0.40. The company has a 50 day simple moving average of $762.17 and a two-hundred day simple moving average of $666.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the company posted $12.07 EPS. The business’s quarterly revenue was up 2.5% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.47%.

Analysts Set New Price Targets

A number of research firms recently issued reports on REGN. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. UBS Group upped their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Cantor Fitzgerald raised their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Finally, Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $793.81.

Insider Activity

In related news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the transaction, the director owned 17,803 shares in the company, valued at $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 3,636 shares of company stock worth $2,862,920. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.